PRNB Principia Biopharma Inc.

100.27
+0.22  (+0%)
Previous Close 100.05
Open 100.05
52 Week Low 25.35
52 Week High 101.89
Market Cap $3,332,595,378
Shares 33,236,216
Float 24,401,337
Enterprise Value $3,023,447,410
Volume 1,974,910
Av. Daily Volume 1,726,455
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
PRN473
Immune-mediated diseases
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Rilzabrutinib PRN1008 - PEGASUS
Pemphigus
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Rilzabrutinib PRN1008
IgG4-related disease (IgG4-RD)
Phase 2
Phase 2
Phase 2 trial has commenced dosing - September 17, 2020.
Rilzabrutinib (PRN1008)
Immune thrombocytopenic purpura (ITP)
Phase 3
Phase 3
Phase 3 trial to be initiated by the end of 2020.
SAR442168 (PRN2246)
Multiple sclerosis
Phase 3
Phase 3
Phase 3 commencement of enrolment announced June 23, 2020.
Rilzabrutinib PRN1008
Pemphigus
Phase 2
Phase 2
Phase 2 Part B open label data presented at AAD June 12, 2020. 60 and 87 percent of patients achieved control of disease activity by the 4th and 12th week, respectively.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to evaluate rilzabrutinib in IgG4-related disease (RD). 

    "IgG4-RD is a serious fibro-inflammatory disease that can affect nearly any organ. The disease has long been under-diagnosed and under-treated, so we believe there is a significant medical need to have fast acting steroid free treatments with persistent responses. We believe rilzabrutinib has the potential to lead to positive outcomes in IgG4-RD by impacting many of the driving effector cells of the…

    SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (NASDAQ:PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to evaluate rilzabrutinib in IgG4-related disease (RD). 

    "IgG4-RD is a serious fibro-inflammatory disease that can affect nearly any organ. The disease has long been under-diagnosed and under-treated, so we believe there is a significant medical need to have fast acting steroid free treatments with persistent responses. We believe rilzabrutinib has the potential to lead to positive outcomes in IgG4-RD by impacting many of the driving effector cells of the disease, including inflammatory monocytes, macrophages, eosinophils, B cells, IgG4+ plasmablasts and cytotoxic T-cells," said Martin Babler, president and chief executive officer of Principia. 

    About the Phase 2A Trial

    This multicenter Phase 2A trial is anticipated to enroll approximately 25 patients with active IgG4-RD in two arms, rilzabrutinib with glucocorticoids or glucocorticoids only. Patients who meet all the inclusion criteria after completion of the four-week screening period will be randomized in a 3:1 ratio to the rilzabrutinib with glucocorticoids arm or the glucocorticoids only arm. The main treatment period is 12 weeks, and patients may then be eligible to enter a treatment extension period of 40 weeks, followed by a four-week safety follow-up period. The primary endpoint of the trial is the proportion of patients who achieve complete remission at week 12 with no glucocorticoid use at Week 4 for the rilzabrutinib arm and week 12 for the glucocorticoids arm.



    About IgG4 Related Disease



    There is significant need for new treatment options for patients with IgG4-RD. IgG4-RD is an immune-mediated disease of chronic inflammation and fibrosis that, if left untreated, can lead to severe morbidity including organ dysfunction and organ failure, which can be fatal. IgG4-related disease typically manifests with multiple organ involvement including but not limited to exocrine glands, GI tract organs (liver, pancreas), and kidneys.



    Treatment is typically glucocorticoids (GCs); however, patients often relapse after GCs are tapered and thus require chronic GC dosing, which can lead to severe and debilitating side effects. Rituximab has been shown to have an effective clinical response; however, patients frequently relapse after treatment as well. Recent advances in the field have led to recognition of this disease and the many unmet needs for the patients diagnosed with it. Awareness and recognition of IgG4-RD is growing, and the exact prevalence remains unknown, with estimates ranging from 40,000 to 180,000 in the United States alone.



    About Rilzabrutinib

     


    Rilzabrutinib, Principia's most advanced drug candidate, is an oral, first-in-class, reversible covalent, Bruton tyrosine kinase (BTK) inhibitor optimized for the treatment of immune mediated diseases. BTK is involved in innate and adaptive immune responses and is a critical signaling molecule in immune mediated diseases. Rilzabrutinib data demonstrates an ability to block inflammatory immune cells, eliminate autoantibody destructive signaling, and prevent new autoantibody production without depleting B cells. Rilzabrutinib's unique attributes are based in the power of the bond from Principia's proprietary Tailored Covalency® platform.  This enabled the company to optimize rilzabrutinib's safety and efficacy profile, with prolonged and reversible action at the target site while being rapidly eliminated from the body. Principia believes this bonding and the limited systemic exposure of rilzabrutinib enables rapid clinical reversibility of effects on the immune system, and it is thus designed for safety in immune mediated diseases. 



    About Principia Biopharma



    Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune mediated diseases. Through Principia's proprietary Tailored Covalency® platform, our strategy is to build and advance a pipeline of best-in-class drug candidates with significant therapeutic benefits, limit unintended side effects, improve quality of life and over time modify the course of disease. This highly reproducible approach enables the company to pursue multiple programs efficiently, having discovered three drug candidates. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a global Phase 3 clinical trial in pemphigus, a Phase 1/2 clinical trial in immune thrombocytopenia (ITP), a Phase 2A clinical trial in IgG4-RD and the company plans to initiate a Phase 3 trial in ITP. PRN2246/SAR442168 is a covalent BTK inhibitor which crosses the blood-brain barrier and is licensed to Sanofi. Sanofi has announced that SAR442168 has entered Phase 3 clinical trials in multiple sclerosis. PRN473 Topical, a topical reversible covalent BTK inhibitor designed for immune-mediated diseases that could benefit from localized application to the skin, is being evaluated in Phase 1 trials.  For more information, please visit www.principiabio.com.



    Forward-Looking Statements

    This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential plans, and future performance, including, but not limited to, Principia's expectations regarding the Principia pipeline of product candidates, the design of, progress of (including the anticipated enrollment for its Phase 2A trial in IgG4-RD), results from, and timing of, its clinical trials and information regarding the timing, scope and success of additional clinical results. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Principia management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Principia, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks relating to the ability to complete and the timing of completion of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement") Principia entered into on August 16, 2020, with Sanofi and Kortex Acquisition Corp. ("Purchaser"), a wholly owned subsidiary of Sanofi, including the parties' ability to satisfy the conditions to the consummation of the tender offer (the "Offer") and the other conditions set forth in the Merger Agreement, the risk that stockholder litigation in connection with the proposed transaction may result in significant costs and the possibility of any termination of the Merger Agreement; the uncertainties inherent in research and development, including future clinical data and analysis, regulatory obligations and oversight by regulatory authorities, such as the FDA, and risks associated with Principia's intellectual property. The forward-looking statements contained in this communication are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Actual results may differ materially from current expectations because of risks associated with uncertainties as to the timing of the Offer and the merger contemplated by the Merger Agreement (the "Merger"); the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the Offer or the Merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Offer or the Merger; the effects of disruption from the transactions of Principia's business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees or vendors. The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Principia's businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. While the list of factors presented here is representative, no list should be considered a statement of all potential risks, uncertainties or assumptions that could have a material adverse effect on the companies' consolidated financial condition or results of operations. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Principia's public filings with the SEC from time to time, including Principia's most recent Annual Report on Form 10-K for the year ended December 31, 2019, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Principia's stockholders and investors are cautioned not to unduly rely on these forward-looking statements. The forward-looking statements speak only as of the date hereof and, other than as required by applicable law, Principia does not undertake any obligation to update or revise any forward-looking information or statements.

    Additional Information and Where to Find It

    In connection with the proposed acquisition of Principia by Sanofi, Purchaser commenced a tender offer for all of the outstanding shares of Principia on August 28, 2020. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Principia nor is it a substitute for the tender offer materials that Sanofi and Purchaser filed with the upon commencement of the tender offer. On August 28, 2020, Sanofi and Purchaser filed tender offer materials on Schedule TO with the SEC and Principia filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the offer. The tender statement on Schedule TO, the offer to purchase, the Solicitation/Recommendation Statement of Principia on Schedule 14D-9 and related materials with respect to the tender offer and the merger are available to Principia's stockholders free of charge at the website of the SEC at www.sec.gov or from the information agent named in the tender offer materials. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by Principia under the "Investors and Media" section of Principia's website at www.principiabio. Principia's stockholders are advised to read the tender offer statement and the solicitation/recommendation statement and any amendments thereto, as well as any other documents relating to the tender offer and the merger that are filed with the SEC, carefully and in their entirety prior to making any decisions with respect to whether to tender their shares into the tender offer because they contain important information, including the terms and conditions of the tender offer.

    In addition to the Solicitation/Recommendation Statement that Principia has filed, Principia files annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any reports, statements or other information filed by Principia at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Principia's filings with the SEC are also available to the public from commercial document-retrieval services and the SEC's website at http://www.sec.gov.



    Investor Contact
    Christopher Chai, CFO
    
    
    Media Contact
    Paul Laland, VP of Corporate Communications
    
    415.519.6610

    Primary Logo

    View Full Article Hide Full Article
  2. SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief Executive Officer of Principia Biopharma, Inc. (NASDAQ:PRNB), to the company's Board of Directors.

    Mr. Babler brings decades of experience in business and commercial development, marketing and leadership in the biopharmaceutical industry. Since joining Principia as CEO in 2011, he has helped build and advance the company's team, scientific platform, and portfolio of therapeutic candidates for immune-mediated diseases. In August 2020, Principia and Sanofi entered…

    SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief Executive Officer of Principia Biopharma, Inc. (NASDAQ:PRNB), to the company's Board of Directors.

    Mr. Babler brings decades of experience in business and commercial development, marketing and leadership in the biopharmaceutical industry. Since joining Principia as CEO in 2011, he has helped build and advance the company's team, scientific platform, and portfolio of therapeutic candidates for immune-mediated diseases. In August 2020, Principia and Sanofi entered into a definitive acquisition agreement valued at approximately $3.7 billion.

    "Martin's expertise in translating scientific innovation into commercial therapeutics and his experience building a platform-based biotechnology company will be valuable additions to the Neoleukin Board as we begin clinical development and continue to expand opportunities for de novo protein design," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We are thrilled to have him join our distinguished Board."

    "Neoleukin's de novo protein design represents a new approach to therapeutic development, and I'm extremely pleased to be joining the company at this exciting time," said Mr. Babler.



    Mr. Babler previously served as President and Chief Executive Officer of Talima Therapeutics from 2007 to 2011. Prior to this, Mr. Babler was a senior executive at Genentech including Vice President, Immunology Sales and Marketing. During his time at Genentech, he oversaw the Commercial Development organization and led the Cardiovascular Marketing organization.

    Mr. Babler began his pharmaceutical industry career at Eli Lilly and Company with positions in sales management, global marketing and business development. He holds a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich. Mr. Babler graduated from the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University. 

    About Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

    Safe Harbor / Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, planned development activities and timelines, use and adequacy of cash reserves and the potential benefits of the company's product candidates and platform. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of such forward-looking statements include but are not limited to statements regarding the therapeutic properties and potential of the company's de novo protein design technology. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company's cash forecasts, the company's ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company's clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin's business and its financial results are detailed under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Contacts:

    Media

    Julie Rathbun

    206-769-9219

    Investors

    Solebury Trout

    Brian Korb

    646-378-2923

    Primary Logo

    View Full Article Hide Full Article
  3. NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

    Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for $100 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/principia-biopharma-inc-prnb-stock-merger-sanofi/.

    Builders FirstSource, Inc. (NASDAQ:BLDR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with BMC Stock Holdings, Inc. Under the terms of the agreement, BMC shareholders will receive 1.3125 shares of Builders FirstSource common stock for each share of BMC common stock. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/builders-firstsource-inc-bldr-stock-merger-bmc/.

    Akcea Therapeutics, Inc. (NASDAQ:AKCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/akcea-therapeutics-inc-akca-stock-merger-ionis/.

    Yintech Investment Holdings Limited (NASDAQ:YIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a group of rollover shareholders that includes members of Yintech's management and board of directors. Under the terms of the merger agreement, holders of Yintech ordinary shares will receive $0.365 in cash per share, and holders of Yintech American depository shares ("ADS") will receive $7.30 in cash per ADS. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/yintech-investment-holdings-limited-yin-stock-merger/.

    Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

    Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email  or .

    Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

    Attorney Advertising. Prior results do not guarantee a similar outcome.

    Contact Information:

    Halper Sadeh LLP

    Daniel Sadeh, Esq.

    Zachary Halper, Esq.

    (212) 763-0060

     

      

    https://www.halpersadeh.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llp-is-investigating-the-following-mergers-shareholders-are-encouraged-to-contact-the-firm--prnb-bldr-akca-yin-301127064.html

    SOURCE Halper Sadeh LLP

    View Full Article Hide Full Article
  4. NEW YORK, Aug. 22, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

    MVC Capital, Inc. (NYSE:MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC and $0.39492 in cash for each share of MVC Capital stock. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/mvc-capital-inc-mvc-stock-merger-barings-bdc.

    Principia Biopharma Inc. (NASDAQ:PRNB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sanofi for $100 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/principia-biopharma-inc-prnb-stock-merger-sanofi/.

    Yintech Investment Holdings Limited (NASDAQ:YIN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a group of rollover shareholders that includes members of Yintech's management and board of directors. Under the terms of the merger agreement, holders of Yintech ordinary shares will receive $0.365 in cash per share, and holders of Yintech American depository shares ("ADS"), each representing twenty shares, will receive $7.30 in cash per ADS. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/yintech-investment-holdings-limited-yin-stock-merger/.

    Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/momenta-pharmaceuticals-inc-stock-merger-jnj.

    Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

    Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email  or .

    Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

    Attorney Advertising. Prior results do not guarantee a similar outcome.

    Contact Information:

    Halper Sadeh LLP

    Daniel Sadeh, Esq.

    Zachary Halper, Esq.

    (212) 763-0060



      

    https://www.halpersadeh.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-investigation-alert-halper-sadeh-llp-investigates-the-following-mergers-shareholders-are-encouraged-to-contact-the-firm--mvc-prnb-yin-mnta-301116669.html

    SOURCE Halper Sadeh LLP

    View Full Article Hide Full Article
  5. NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:

    • NTN Buzztime, Inc. (NYSE:NTN)

    NTN Buzztime has signed an agreement to merge with Brooklyn ImmunoTherapeutics. Under the proposed transaction, shareholders of NTN will own only 5.92% of the combined company.

    • Principia Biopharma Inc. (NASDAQ: PRNB)

    Principia Biopharma has agreed to be acquired by Sanofi.  Under the proposed transaction, shareholders of Principia will receive $100.00 in cash for every share owned.

    • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals has agreed to be acquired by Johnson & Johnson.  Under the proposed transaction, shareholders of Momenta will receive $52.50 in cash for every share owned.

    • Pfenex Inc. (NYSE:PFNX)

    Pfenex has agreed to be acquired by Ligand Pharmaceuticals.  Under the proposed transaction, shareholders of Pfenex will receive $12.00 in cash and one contingent value right  for every share owned.

    Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process. 

    Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at or telephone at (212) 709-8245.  The consultation and case are free with no obligation to you.  Moore Kuehn pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

    Moore Kuehn is a 5-star Google rated New York City law firm with attorneys representing investors and consumers in litigation involving securities laws, fraud, breaches of fiduciary duties, and other claims.  For additional information about Moore Kuehn, please visit http://www.moorekuehn.com/practice/new-york-securities-litigation/.

    Attorney advertising. Prior results do not guarantee similar outcomes.

    Contacts:

    Moore Kuehn, PLLC

    Justin Kuehn, Esq.

    30 Wall Street, 8th Floor

    New York, New York 10005

     

    (212) 709-8245

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moore-kuehn-encourages-ntn-prnb-mnta-and-pfnx-investors-to-contact-law-firm-301115916.html

    SOURCE Moore Kuehn, PLLC

    View Full Article Hide Full Article
View All Principia Biopharma Inc. News